Cancer Immunosuppression and How to Conquer it

Live Webinar from MedChem Express

MedChem ExpressMedChem Express offers a wide range of high-quality research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Product identity, quality, purity and activity are assured by their robust quality control programs and procedures.

Join MedChem's upcoming webinar on cancer immunosuppression.

Live Webinar: Cancer Immunosuppression and How to Conquer it

T-cell-oriented cancer immunotherapy, most triumphed by immune checkpoint blockade (ICB) and CAR-T therapies, has transformed the cancer treatment landscape and benefited many patients. However, de novo and acquired resistance to these therapies remains a significant challenge. Our recent works illuminate some immunosuppression mechanisms in prostate cancer and breast cancer, where both cancer-cell-intrinsic and -extrinsic pathways contribute to the formation of an immunosuppressive microenvironment, suggesting a concerted targeting strategy is required to overcome immunosuppression and enable immunotherapy efficacy.

We identified emerging strategies, including molecularly targeted therapy and dietary interventions. The use of single-cell technologies greatly facilitates understanding the immunocyte changes in response to the experimental therapeutics and helps guide the following steps to improve the efficacy further. The goal of our research is ultimately tipping the survival curves to a complete “flat tail” – the dream of cancer immunotherapy.

In this webinar, you will learn:

• The role of the tumor microenvironment in cancer immunology and immunotherapy, focusing on cancer-cell-intrinsic
  and -extrinsic mechanisms of immune evasion and immunotherapy resistance.

• Strategies to improve the efficacy of immune checkpoint blockade drugs by combining with other therapy modalities.

• The application of single-cell technologies, such as single-cell RNA sequencing, to study changes in immunocytes in
  response to experimental therapeutics, offering insights into the genomic, genetic and molecular mechanisms of
  tumor immunology.

Speaker: Xin Lu, Ph.D., John M. and Mary Jo Boler Collegiate Associate Professor, University of Notre Dame

Date and TimeWednesday, March 13, 2024, 3:00 PM (CET)

Register for the webinar


Other News

AbBy Fluor® antibody conjugates from Bioss

AbBy Fluor® Dyes

Antibody conjugates from Bioss

Superior Yeast & Fungi Lysis

New: Zymolyase Ultra

Efficient Yeast & Fungi Lysis in 10 Minutes!

MolBoolean - Beyond proximity ligation

New: MolBoolean™

Unlock the secrets of protein-protein interactions

Webinars Spring 2024

Scientific Webinars...

Vector Labs, Sino Biological, Cygnus Technologies i.a.

New Alexa Fluor® 555 and Alexa Fluor® 568 conjugates from Jackson ImmunoReasearch

Secondary Antibodies

New AF555 and AF568 conjugates from Jackson